{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:52:46Z","timestamp":1761630766328,"version":"3.37.3"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.dld.2016.10.001","type":"journal-article","created":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T05:15:09Z","timestamp":1476681309000},"page":"157-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-\u03b1 inhibitors and conventional immunosuppressants"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5128-3846","authenticated-orcid":false,"given":"Fabio Salvatore","family":"Macaluso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Maida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Renna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Affronti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Sapienza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariangela","family":"Dimarco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosalba","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Rizzuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Cottone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ambrogio","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2016.10.001_bib0005","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","article-title":"European Crohn\u2019s and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn\u2019s disease: current management","volume":"4","author":"Dignass","year":"2010","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2016.10.001_bib0010","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.crohns.2012.09.002","article-title":"Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management","volume":"6","author":"Dignass","year":"2012","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2016.10.001_bib0015","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/gut.35.3.360","article-title":"Frequency of glucocorticoid resistance and dependency in Crohn\u2019s disease","volume":"35","author":"Munkholm","year":"1994","journal-title":"Gut"},{"key":"10.1016\/j.dld.2016.10.001_bib0020","doi-asserted-by":"crossref","first-page":"9675","DOI":"10.3748\/wjg.v20.i29.9675","article-title":"Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease","volume":"20","author":"Renna","year":"2014","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2016.10.001_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.dld.2010.07.010","volume":"43","author":"Orlando","year":"2011","journal-title":"Digestive and Liver Disease"},{"key":"10.1016\/j.dld.2016.10.001_bib0030","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.dld.2015.12.016","article-title":"GIVI (Gruppo Italiano su Vedolizumab nelle IBD) Group. Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease","volume":"48","author":"Armuzzi","year":"2016","journal-title":"Digestive and Liver Disease"},{"key":"10.1016\/j.dld.2016.10.001_bib0035","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/tri.12554","article-title":"Mycophenolate revisited","volume":"28","author":"Van Gelder","year":"2015","journal-title":"Transplant International"},{"key":"10.1016\/j.dld.2016.10.001_bib0040","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0190-9622(99)70203-3","article-title":"Mycophenolate mofetil in autoimmune and inflammatory skin disorders","volume":"40","author":"Nousari","year":"1999","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1016\/j.dld.2016.10.001_bib0045","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1111\/j.1572-0241.1998.00606.x","article-title":"Mycophenolate mofetil in patients with Crohn's disease","volume":"93","author":"Fickert","year":"1998","journal-title":"The American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2016.10.001_bib0050","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/gut.44.5.625","article-title":"Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease","volume":"44","author":"Neurath","year":"1999","journal-title":"Gut"},{"key":"10.1016\/j.dld.2016.10.001_bib0055","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/j.1572-0241.2000.02010.x","article-title":"Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study","volume":"95","author":"Orth","year":"2000","journal-title":"The American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2016.10.001_bib0060","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1365-2036.2000.00695.x","article-title":"Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease","volume":"14","author":"Fellermann","year":"2000","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2016.10.001_bib0065","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/00054725-200002000-00003","article-title":"Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease","volume":"6","author":"Hassard","year":"2000","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2016.10.001_bib0070","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.1572-0241.2001.03622.x","article-title":"Is mycophenolate mofetil an effective alternative in azathioprine intolerant patients with chronic active Crohn's disease?","volume":"96","author":"Miehsler","year":"2001","journal-title":"The American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2016.10.001_bib0075","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00054725-200203000-00004","article-title":"Toxicity of mycophenolate mofetil in patients with inflammatory bowel disease","volume":"8","author":"Skelly","year":"2002","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2016.10.001_bib0080","first-page":"17","article-title":"Mycophenolate mofetil in refractory Crohn's disease after failure of treatments by azathioprine or methotrexate","volume":"26","author":"Hafraoui","year":"2002","journal-title":"Gastroenterologie Clinique et Biologique"},{"key":"10.1016\/j.dld.2016.10.001_bib0085","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2036.2004.01856.x","article-title":"Mycophenolate mofetil for Crohn's disease: short-term efficacy and long-term outcome","volume":"19","author":"Wenzl","year":"2004","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2016.10.001_bib0090","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/ibd.20258","article-title":"Mycophenolate mofetil therapy for refractory inflammatory bowel disease","volume":"13","author":"Palaniappan","year":"2007","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2016.10.001_bib0095","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3748\/wjg.15.1594","article-title":"Use of mycophenolate mofetil in inflammatory bowel disease","volume":"15","author":"Tan","year":"2009","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2016.10.001_bib0100","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/j.1365-2036.2011.04825.x","article-title":"Mycophenolate mofetil following intolerance or failure of thiopurine therapy in inflammatory bowel diseases","volume":"34","author":"McDermott","year":"2011","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2016.10.001_bib0105","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.crohns.2014.01.014","article-title":"Mycophenolate mofetil therapy in the management of inflammatory bowel disease\u2014a retrospective case series and review","volume":"8","author":"Smith","year":"2014","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2016.10.001_bib0110","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.crohns.2009.12.003","article-title":"European Crohn\u2019s and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis","volume":"4","author":"Van Assche","year":"2010","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2016.10.001_bib0115","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.crohns.2012.09.003","article-title":"Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis","volume":"61","author":"Dignass","year":"2012","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2016.10.001_bib0120","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.cgh.2015.12.022","article-title":"Selective use of combination therapy in patients with infliximab-resistant inflammatory bowel disease: data from a Tertiary Referral Center","volume":"14","author":"Orlando","year":"2016","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2016.10.001_bib0125","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjw089","article-title":"The selective use of combination therapy in patients with inflammatory bowel disease resistant to anti-TNF: to whom, how and how long?","author":"Macaluso","year":"2016","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2016.10.001_bib0130","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2016.02.085","article-title":"The METEOR trial: the Burial of Methotrexate in Ulcerative colitis?","author":"Macaluso","year":"2016","journal-title":"Gastroenterology"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865816307472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865816307472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T02:15:36Z","timestamp":1668564936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865816307472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S1590865816307472"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2016.10.001","relation":{},"ISSN":["1590-8658"],"issn-type":[{"type":"print","value":"1590-8658"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-\u03b1 inhibitors and conventional immunosuppressants","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2016.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}